Since the approval of the first chimeric antigen receptor T-cell therapy, the research community has grappled with a crucial question.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045
CAR-T poised to create ‘paradigm shift’ in non-Hodgkin lymphoma
Default sub title
minute read
by Healio | February 14, 2022
